Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Jun 16, 2022; 10(17): 5566-5576
Published online Jun 16, 2022. doi: 10.12998/wjcc.v10.i17.5566
Table 1 Demographic and clinical variables in patients with chronic hepatitis C stratified by treatment status (n = 813)
Variables
HCV treated
HCV untreated
(n = 419 (51.5%)]
[n = 394 (48.5%)]
Age (yr) [mean (SD)]56.54 (8.26)56.14 (9.02)
Male sex [n (%)]285 (68.02)234 (59.39)
Race [n (%)]
Black339 (80.91)303 (77.49)
Other18 (4.30)20 (5.12)
White62 (14.80)68 (17.39)
Smoking history
Non-smoker70 (16.71)98 (25.00)
Current smoker216 (51.55)183 (46.68)
Former smoker133 (31.74)111 (28.32)
Co-infections [n (%)]
HIV184 (43.91)113 (28.68)
HBV9 (2.15)15 (3.81)
HCV RNA at baseline, IU/mL [median (Q1, Q3)]2220000 (803000, 6606934)2340000 (693015, 5924209)
Biochemistry
AST, IU/L, mean (SD)57.91 (44.75)46.38 (31.13)
ALT, IU/L, mean (SD)56.63 (51.54)51.52 (59.04)
Bilirubin < 2 mg/dL [n (%)]393 (97.52)359 (98.09)
Platelets, K/uL, median (Q1, Q3)196.00 (155.50, 238.00)209.00 (170.50, 255.00)
Hepatocellular carcinoma [n (%)]4 (0.95)2 (0.51)
Baseline diabetes [n (%)]82 (19.57)73 (18.53)
Baseline chronic kidney disease [n (%)]41 (9.79)26 (6.60)